Study #2024-1631
A phase 3 randomized double-blind study of adjuvant pembrolizumab with or without V940 in participants with resectable Stage II to IIIB (N2) NSCLC not achieving pCR after receiving neoadjuvant pembrolizumab with platinum-based doublet chemotherapy (INTerpath-009)
MD Anderson Study Status
Enrolling
Treatment Agent
Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Gemcitabine, Paclitaxel, Intismeran autogene
Description
The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene and pembrolizumab after surgery can help prevent the cancer from coming back in people with non-small cell lung cancer (NSCLC) whose tumors did not respond completely to treatment before surgery (neoadjuvant treatment).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Carcinoma, Non-Small-Cell Lung
Study phase:
Phase III
Physician name:
Tina Cascone
Department:
Thoracic/Head & Neck Medical Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.